Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial

Bjørn H Ebdrup^{1

2}, Brian V Broberg¹, Pelle L Ishøy¹, Nikolaj Bak¹, Ulrik B Andersen³, Niklas R Jørgensen^{4

5}, Jens J Holst⁶, Filip K Knop^{2

6

7}, Birte Y Glenthøj^{1

2}

Affiliations

¹ Centre for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
² Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Glostrup, Denmark.
⁴ Departments of Clinical Biochemistry and Medicine, Research Centre for Ageing and Osteoporosis, Rigshospitalet, University of Copenhagen, Glostrup, Denmark.
⁵ OPEN, Odense Patient Data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁷ Centre for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Published Erratum

Bjørn H Ebdrup et al. Diabetes Obes Metab. 2018 May.

. 2018 May;20(5):1327-1328.

doi: 10.1111/dom.13204. Epub 2018 Jan 23.

Bjørn H Ebdrup^{1

2}, Brian V Broberg¹, Pelle L Ishøy¹, Nikolaj Bak¹, Ulrik B Andersen³, Niklas R Jørgensen^{4

5}, Jens J Holst⁶, Filip K Knop^{2

6

7}, Birte Y Glenthøj^{1

2}

¹ Centre for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
² Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Glostrup, Denmark.
⁴ Departments of Clinical Biochemistry and Medicine, Research Centre for Ageing and Osteoporosis, Rigshospitalet, University of Copenhagen, Glostrup, Denmark.
⁵ OPEN, Odense Patient Data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁷ Centre for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

No abstract available

Erratum for

Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY, Ebdrup BH. Ishøy PL, et al. Diabetes Obes Metab. 2017 Feb;19(2):162-171. doi: 10.1111/dom.12795. Epub 2016 Nov 14. Diabetes Obes Metab. 2017. PMID: 27717222 Free PMC article. Clinical Trial.

1. Ishøy PL, Knop FK, Broberg BV, et al. Treatment of antipsychotic‐associated obesity with a GLP‐1 receptor agonist–protocol for an investigator‐initiated prospective, randomised, placebo‐controlled, double‐blinded intervention study: the TAO study protocol. BMJ Open. 2014;4(1):e004158. - PMC - PubMed
1. Ishøy PL, Knop FK, Broberg BV, et al. Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial. Diabetes Obes Metab. 2017;19(2):162‐171. - PMC - PubMed
1. Siskind D, Russell AW, Gamble C, et al. Treatment of clozapine‐associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial. Diabetes Obes Metab. 2018;20:1050–1055. - PubMed
1. Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of Liraglutide treatment on prediabetes and overweight or obesity in clozapine‐ or olanzapine‐treated patients with schizophrenia spectrum disorder. JAMA Psychiat. 2017;74(7):719. - PMC - PubMed